Brief: Solid Biosciences Ends Third Quarter With About $142.2 Million In Cash

Solid Biosciences

10/11/2022 13:07

Nov 10 (Reuters) - Solid Biosciences Inc  SLDB.O :
    * COMPANY ENDS Q3 WITH APPROXIMATELY $142.2 MILLION IN CASH
AND
INVESTMENTS; ANTICIPATED CASH RUNWAY INTO Q2 2024
    * ENDS Q3 WITH APPROXIMATELY $142.2 MILLION IN CASH AND
INVESTMENTS; ANTICIPATED CASH RUNWAY INTO Q2 2024
    * SOLID BIOSCIENCES - ON TRACK FOR ANTICIPATED MID-2023 IND
SUBMISSION FOR SGT-003, PENDING IND ACCEPTANCE, FIRST PATIENT
DOSING IN LATE-2023
    * NET LOSS FOR Q3 OF 2022 WAS $20.4 MILLION VERSUS $18.0
MILLION
    * SOLID BIOSCIENCES - EXPECTS TO CLOSE ACQUISITION OF
AAVANTIBIO
AND $75 MILLION PRIVATE PLACEMENT BY YEAR-END
    * Q3 EARNINGS PER SHARE VIEW $-2.67 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX1tylYQ 
Further company coverage:  SLDB.O 
 ((reuters.briefs@thomsonreuters.com;))